Article

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

2022-01-27

Abstract excerpt

<title>Abstract</title> <p>The mammalian SWI/SNF helicase SMARCA4 is frequently mutated in cancer and inactivation results in a cellular dependence on its paralog, SMARCA2, thus making SMARCA2 an attractive synthetic lethal target. However, published data indicates that achieving a high degree of selective SMARCA2 inhibition is likely essential to afford an acceptable therapeutic index, and realizing this objecti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 71e1aee9-cf6d-5e61-a104-6e1b2761fbf8
DOI: 10.21203/rs.3.rs-1133243/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancersDOI 10.21203/rs.3.rs-1133243/v1Read

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.Semantic proximity Read

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.Semantic proximity Read

Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 2023Semantic proximity Read

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivoSemantic proximity Read

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C InhibitorsSemantic proximity Read

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read

Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer.Semantic proximity Read

Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.Semantic proximity Read

Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity Read

PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspectiveSemantic proximity Read

Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment.Semantic proximity Read

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor RegressionSemantic proximity Read